EMA Application withdrawn: Abylqis (arachis hypogaea extract) — DBV Technologies

View source ↗

Summary

The EMA has withdrawn the application for Abylqis (arachis hypogaea extract) by DBV Technologies for peanut hypersensitivity.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peanut Hypersensitivity

Drugs mentioned

• Abylqis (arachis hypogaea extract)

Snippet

Status: Application withdrawn. Therapeutic area: Peanut Hypersensitivity. MAH: DBV Technologies